horiz (2)horiz (2)horiz (2)horiz (2)
  • Solutions
    • PepsinCheck
    • Reflux Band
    • Dx-pH System
    • Stretta
    • Secca
  • Clinicians
  • Patients
  • Blog
  • Events
  • Clinical Library
  • Login
✕
4 Reasons Why Your Patient’s LPR Symptoms Didn’t Improve Despite PPI Therapy
January 30, 2018
“Early Referral for Esophageal pH Monitoring is More Cost-Effective than Prolonged Empiric Trials of PPIs for Suspected Gastroesophageal Reflux Disease”
February 28, 2018

By: Craig H. Zalvan, MD, FACS
Chief of Otolaryngology and Medical Director
The Institute for Voice and Swallowing Disorders

 

CASE HISTORY & EVALUATION

66 year old male presents with diagnosis of GERD and asthma for chronic cough. He reports being well until 5 years ago when he had a severe URI, symptoms of which resolved, except for a chronic cough. Additional symptoms of ongoing waterbrash, throat clearing, and globus sensation; a tickle sensation in the throat followed by spasms of coughing associated with bouts of “wheezing,” described as a high pitch sound when breathing inward. He also reports his eyes tearing, rhinorrhea, and vocal strain with occasional bouts of nausea. Cold air and talking trigger coughing episodes.

Prior treatment included multiple courses of antibiotics, steroids, and allergy medications with no change in symptoms. A GI put him on twice daily PPI therapy that did seem to decrease coughing at night but not during the day. ENT evaluation was reported as normal. Pulmonology evaluation demonstrated normal PFT, yet diagnosis was “cough variant asthma.” Patient was placed on an inhaled steroid and bronchodilator (which at times triggered coughing) with no significant improvement. CT of the sinus, CXR, CT of the chest were all WNL. His initial Reflux Symptom Index, RSI=36; initial Cough Symptom Index, CSI=32. 

Evaluation revealed normal sinus anatomy and laryngoscopy demonstrated a slight left vocal paresis, normal upper trachea, and findings consistent with LPR – moderate posterior glottic edema, vocal fold edema, sub-vocal fold edema, and obliteration of the ventricle. Transnasal esophagoscopy demonstrated mild esophagitis with LA Grade A findings.

Oropharyngeal pH testing was ordered given the chronicity of his symptoms and lack of response to most medications. Testing was performed while on PPI therapy, as cessation of the medications resulted in significantly increased burning and coughing at night.

Zalvan Case Study Graph
Results of the oropharyngeal pH testing revealed an interesting pattern of LPR followed by coughing episodes. There were 85 events < pH 5.5 with 6 concurrent coughing spasms; remaining coughing spasms occurred immediately after a reflux event. Overall there was over 4.5 hours with pH<5.5 (the majority of time when supine). Ryan score Upright=130 (Nl<9.41)1 

DIAGNOSIS

Given the close association with his initial URI, a diagnosis of a post-viral neurogenic chronic cough with post-viral LPR exacerbation causing the night-time coughing and acting as a day-time trigger.

ABOUT LPR

Laryngopharyngeal reflux disease (LPRD) represents a spectrum of symptoms affecting the upper aerodigestive tract, including: throat clearing, globus sensation, dysphagia, waterbrash, hoarseness, and chronic cough. LPR is thought to be caused by exposure of the laryngopharyngeal tissues to acid in the presence of pepsin, with resulting inflammation.

Diagnosis is typically based on history and physical examination with oropharyngeal pH testing utilized for recalcitrant symptoms, confounding factors, and diagnostic dilemmas.

Treatment is controversial and has historically utilized proton pump inhibitors (PPI), despite questionable potential efficacy2 and negative side effects including: increased rates of heart attack, dementia, and overall rates of death for long term use3. Over 13 billion dollars4 are spent yearly in attempt to treat this disease, primarily due to the cost of drug utilization. Recent evidence suggests that a mostly plant based, Mediterranean style diet, with the use of alkaline water, can significantly control this disease as well, if not better, than PPI5.

DISCUSSION

Chronic cough is a diagnostic dilemma resulting in significant expenditure of time, money, and resources. In the otolaryngology world, the causes of chronic cough can be broken down into four main categories: sinus, pulmonary, reflux-related, and intrinsic to the larynx. 

Sinus: This patient had prior treatment for sinus disease and had a normal sinus CT. Sinus disease can certainly cause coughing from increased volume of nasal drainage of mucus, allergic mucin, and pus; however, should be associated with other symptoms of headache, fever, facial pain, pressure, sneezing, rhinorrhea, and malaise as well as physical findings on endoscopy demonstrating drainage of thick mucus, pus, inflammatory polyps, and/or bleeding. The addition of CT scanning of the sinus would also demonstrate significant abnormalities suggesting the sinuses as the cause. 

The pulmonary workup was completely normal despite being labeled as “cough-variant asthma” and he had no response to multiple inhalers. The addition of a normal CT of the chest, CXR, and PFT sheds significant doubt on the diagnosis of “cough-variant asthma”. Cough variant asthma does exist as a real entity: chronic cough with high sputum eosinophilia, reversible airway disease, and response to inhaled steroids/bronchodilators. Nearly all of the chronic cough patients seen in the laryngology practice for chronic cough do not fit into this criteria. Neurogenic cough is far more common and likely represents the vast majority of cough variant asthma patients6, typically consisting of chronic cough preceded by a tickle sensation followed by coughing spasms often associated with epiphora, rhinorrhea, vocal strain, and nausea. The cough is often triggered by talking, laughing, eating, drinking, cold air, and odors. These spasms of coughing can be accompanied by bouts of inspiratory stridor, often misdiagnosed as “wheezing” further propagating the false diagnosis of asthma. Treatment in our clinic is first based on trigger reduction: saline irrigations and topical steroids/antihistamines to decrease and thin the basal rate of mucus from the sinuses, often upwards of 1L or more. 

Reflux-related: LPR represents another potential trigger and our data suggest a dietary approach using a mostly plant based, Mediterranean style diet of fruits, vegetables, grains, and nuts with alkaline water decreases LPR and removes the potential trigger effect. In addition to treating reflux, our diet approach helps protect against diabetes, stroke, heart disease, and many cancers7. Our results* demonstrate upwards of 70% of people experience a more than 50% reduction in coughing using this approach alone, without medications†. Lastly, LPR itself can be a cause of chronic coughing, often with night-time awakening as one of the symptoms and treatment is mostly diet based. 

TREATMENT

Trigger reduction therapy was initiated: nasal saline irrigation and nasal antihistamine/steroid combination sprays to decrease and thin the basal rate and consistency of nasal secretions. LPR was treated using a plant based, Mediterranean style diet of 90-95% fruits, vegetables, grains, and nuts; and alkaline water (pH>8.0). Patient’s PPI’s were reduced to a single evening dose. Within 1 week he reported substantial improvement with his daytime coughing and complete cessation of coughing while sleeping. He lost 6 pounds and was instructed to taper off the PPI. By his next visit 6 weeks later, he had lost a total of 10 pounds and his coughing during the day also had improved greatly. His follow-up RSI=8 and his CSI=6 with complete cessation of his PPI.

TAKE HOME POINTS

1. Oropharyngeal pH testing is an important tool in determining the presence of reflux or the absence of reflux.
2. Most patients presenting to the laryngology clinic have seen multiple other physicians and have tried multiple other approaches and medication with failure.
3. Oropharyngeal pH testing can be utilized to demonstrate ongoing LPR despite being on PPI therapy, further underlining the need for major dietary changes. Additionally, oropharyngeal pH testing can demonstrate the absence of reflux supporting the diagnosis of chronic neurogenic cough.

* manuscript in preparation
† Neuromodulating drugs such as amitriptyline can be utilized

 


REFERENCES

1 Ayazi S, Lipham JC, Hagen JA, et al. A New Technique for Measurement of Pharyngeal pH: Normal Values and Discriminating pH Threshold. J Gastrointest Surg. 2009 Aug;13(8):1422-9.
2 Karkos PD, Wilson JA. Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review. Laryngoscope 2006;116:144-8.
3 Corsonello A, Lattanzio F, Bustacchini S , et al. Adverse events of proton pump inhibitors: potential mechanisms. Curr Drug Metab. 2017 Dec 7. doi:
10.2174/1389200219666171207125351. [Epub ahead of print]
4 Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Digest Dis Sci 2011;56:931-50.
5 Zalvan CH, Hu S, Greenberg B, Geliebter J. A Comparison of Alkaline Water and Mediterranean Diet vs Proton Pump Inhibition for Treatment of Laryngopharyn
geal Reflux. JAMA Otolaryngol Head Neck Surg. 2017 Oct 1;143(10):1023-1029. doi: 10.1001/jamaoto.2017.1454.
6 Bastian RW. Diabolical Coughing-Prima Facie Protocols for Diagnosis and Treatment of Medically Jaded Patients. JAMA Otolaryngol Head Neck Surg. 2016 Sep
1;142(9):889-90. doi: 10.1001/jamaoto.2016.0973.
7 Orlich MJ, Singh PN, Sabate J, et al. Vegetarian dietary patterns and mortality in Adventist Health Study 2. JAMA Intern Med 2013;173:1230-8.

Share

Related posts

March 3, 2022

Study finds significant correlation between LPR and Allergic Rhinitis


Read more
January 18, 2021

16 Million New Patients Covered for Stretta Therapy


Read more
November 19, 2020

Minimally Invasive Stretta Antireflux Procedure Accessible to Millions more Patients


Read more
66 Year Old Male with Chronic Cough on Long-term PPIs
CONTACT

US: +800.352.1512
Int'l: +1 858.673.3700
Fax: 858.673.3783 contact@restech.com

Contact

Distributor Login
Clinician Login
Representative Login

How we Help

Solutions
PepsinCheck
Reflux Band
Restech
Stretta
Secca

About Us

Company
Contact Us
Job Opportunities
International Distributors
Compliance
Privacy Policy
Terms of Use

Follow Us

Respiratory Technology Corporation 11011 Brooklet Dr, Ste 300 Houston TX 77099 | © 2019 Restech. All Rights Reserved.
    FIND A DOCTOR
      Bree Gorman, VP Marketing

      Bree has been an integral part of Restech from the very beginning. She holds a Masters in Public Health from George Washington University, a BFA from The University of Kansas in Visual Communications, and is a National Board Certified Health & Wellness Coach. Her command of marketing, public health/health delivery systems, and human health behavior change gives her a unique perspective in developing effective marketing strategies for the company.  

      Physicians: Fill out the form below to complete your request to be added to the “Find-A-Doctor” map on restech.com

       


      Thomas Ball, PhD, VP Clinical Affairs

      Thomas previously worked as a polysomnographic technologist in the Virginia Mason system, before  moving into sales with Restech in 2007. After spending 9 years working with distributors across Europe, he was moved into an organizational role at the head office in Houston. In this capacity he works closely with sales and marketing to provide clinical support, manages clinical studies, and provides clinical perspectives on business development. In his spare time Thomas plays rugby for Houston Athletic Rugby Club.

      Jeff Klindworth, VP Business Development

      Jeff has over 30 years of experience in the medical device industry and previously worked in sales at companies such as Encision Inc., Interventional Therapies, LLC, Boston Scientific, and United States Surgical Corporation. He has been working as the VP of Sales for Mederi Therapeutics since 2009 and now brings his extensive expertise to Restech.  Jeff was part of the team that bridged the Mederi asset sale to Restech.  His clinical knowledge of the Stretta and Secca technologies is invaluable.  Jeff has three decades of physician relations experience that he brings to Restech as part of the leadership team.

      Ray Bengermino, VP Sales

      Ray joined Restech in May 2018 as the Vice President for Sales. He has been in the medical device, and specifically in the GERD space for more than 18 years. Starting in sales at Sandhill Scientific pH diagnostics, he moved on to Curon Medical when Stretta and Secca were first introduced to the market. He then worked for Given Imaging when Curon closed operations.  When Stretta was relaunced he joined Mederi as VP of Sales.  Ray was instrumental in keeping Stretta alive and the customer based informed when Mederi ceased operation and assets were purchased by Restech.  He is part of the leadership team directing all product sales for Restech. Ray graduated from Old Dominion University in Norfolk with a BS in Marketing and Business Administration.

      Mark Clark, CPA, CFO

      Mark is a seasoned professional and Certified Public Accountant in Texas who brings a unique blend of creative vision and financial expertise to any leadership team. He worked as a Senior Executive for 15 years on a leadership team which grew a private equity backed cash logistics company performing at negative EBITDA on $100 million revenue into an international industry leader with superior profitability on revenue exceeding $1.5 billion. In addition, he spent 10 years as a Senior Manager at Price Waterhouse delivering results-oriented merger & acquisition, audit and strategic consulting services to middle market clientele including over 40 manufacturing, distribution, service, nonprofit and technology clients. Mark currently serves as a Chief Financial Officer and consulting CFO (seven years) providing in-house and outsourced CFO and transactional services to the middle market.

      Larry Suarez

      Larry is the CTO for Restech and holds a B.S. in Computer Science. He is a software architect specializing in remote patient monitoring, medical sensors, and clinical trial software. Larry holds a patent on massively distributed computing and has worked for a number of major software startup companies including Sybase, Oracle, and Teradata.  Larry was also the co-founder of a startup to deliver advanced clinical pathways to patients using mobile devices and medical sensors. Larry is truly a pioneer and now a veteran in the deployment.

      Jeff Schipper

      Jeff has a breadth of experience with over 25 years in engineering and executive positions within major fortune 100 healthcare companies. He also has proven success in startup medical technology companies. Jeff provides leadership in securing and managing Restech’s patent portfolio. He also built Restech’s compliance platform that established regulatory acceptance in 25+ countries worldwide. Jeff’s scientific support and in-depth understanding of the device industry set the foundation for current and future commercial innovations at Restech.

      Leo Roucher

      With nearly 30 years of working with physician thought leaders developing novel and emerging technologies, Leo has played a key role in the development and evolution of balloon angioplasty and stent technologies that revolutionized the therapy of cardiac disease. His experience was instrumental in the development of the patented platform technology which drives the Restech sensor. Leo provides a vision and passion for effecting change in the diagnosis and management of atypical reflux.

      Deb Krahel

      With over 20 years of executive experience in both the private and public sector, Debra brings a broad understanding of healthcare delivery system. With experience managing products aimed at wide scale disease and population management for 20 million subscribers, Debra has extensive experience in effectively and efficiently developing models of delivery that address specific health issues. Debra has also been involved in the legislative process and served as the elected President of the Independent Physician Association of California. Debra is dedicated to bringing tools to the healthcare market that improve and support the clinical process.